Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2020

Noé Johannes, Lovejoy Alex, Ou Sai-Hong Ignatius, Yaung Stephanie J, Bordogna Walter, Klass Daniel M, Cummings Craig A, Shaw Alice T

Abstract excerpt

INTRODUCTION: The effectiveness of ALK receptor tyrosine kinase (ALK) inhibitors can be limited by the development of ALK resistance mutations. This exploratory analysis assessed the efficacy of alectinib in patients with NSCLC and ALK point mutations using pooled data from two single-arm phase II studies. METHODS: Studies NP28673 and NP28761 enrolled adults with locally advanced/metastatic ALK-positive NSCLC who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carbazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Mutation

Share to Piperidines

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 31712133
DOI: 10.1016/j.jtho.2019.10.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.PMID 31712133Read ↗

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.Semantic proximity Read ↗

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.Semantic proximity Read ↗

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancerSemantic proximity Read ↗

Alectinib for advanced ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.Semantic proximity Read ↗

Clinical and molecular characteristics of 42 Danish patients with metastatic ALK fusion-positive lung cancer treated with first-line alectinib: A nationwide study.Semantic proximity Read ↗

Plasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX studySemantic proximity Read ↗

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.Semantic proximity Read ↗

Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Semantic proximity Read ↗

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.